Hypertrophic pachymeningitis: Three adult cases and a review of the literature

Akihiro Ueda, Madoka Ueda, Takateru Mihara, Shinji Ito, Kunihiko Asakura, Tatsuro Mutoh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hypertrophic pachymeningitis (HP) is thought to have an autoimmune etiology but its precise cause and treatment remains to be elucidated. Here, we report the clinical details and therapeutic responses of 3 patients with HP and reviewed 66 previously reported cases in the literature. Among these patients, headache was the most frequent complaint. Cranial nerve involvement was also frequently observed, with the optic nerve being the most frequently impaired followed by the oculomotor, trochlear, and abducens nerves in frequency. Elevated C-reactive protein levels and erythrocyte sedimentation rates were found in approximately 97% of the patients. Steroids were the most commonly prescribed therapy, but no definite protocols for the standard dose and duration in HP have been proposed thus far. The average initial dose of prednisolone (PSL) was 42.7 mg/day, and the average maintenance dose was 12.4 mg/day in the chronic stage. Recurrence occurred in many patients when the dose of PSL was reduced to under 20 mg/day. Therefore, steroids should be tapered extremely slowly.

Original languageEnglish
Pages (from-to)243-247
Number of pages5
JournalClinical Neurology
Volume51
Issue number4
DOIs
Publication statusPublished - 01-04-2011

Fingerprint

Meningitis
Prednisolone
Trochlear Nerve
Steroids
Abducens Nerve
Oculomotor Nerve
Cranial Nerves
Blood Sedimentation
Optic Nerve
C-Reactive Protein
Headache
Therapeutics
Recurrence

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Ueda, Akihiro ; Ueda, Madoka ; Mihara, Takateru ; Ito, Shinji ; Asakura, Kunihiko ; Mutoh, Tatsuro. / Hypertrophic pachymeningitis : Three adult cases and a review of the literature. In: Clinical Neurology. 2011 ; Vol. 51, No. 4. pp. 243-247.
@article{22e25e70f9944f17b0b8da75a9b786b0,
title = "Hypertrophic pachymeningitis: Three adult cases and a review of the literature",
abstract = "Hypertrophic pachymeningitis (HP) is thought to have an autoimmune etiology but its precise cause and treatment remains to be elucidated. Here, we report the clinical details and therapeutic responses of 3 patients with HP and reviewed 66 previously reported cases in the literature. Among these patients, headache was the most frequent complaint. Cranial nerve involvement was also frequently observed, with the optic nerve being the most frequently impaired followed by the oculomotor, trochlear, and abducens nerves in frequency. Elevated C-reactive protein levels and erythrocyte sedimentation rates were found in approximately 97{\%} of the patients. Steroids were the most commonly prescribed therapy, but no definite protocols for the standard dose and duration in HP have been proposed thus far. The average initial dose of prednisolone (PSL) was 42.7 mg/day, and the average maintenance dose was 12.4 mg/day in the chronic stage. Recurrence occurred in many patients when the dose of PSL was reduced to under 20 mg/day. Therefore, steroids should be tapered extremely slowly.",
author = "Akihiro Ueda and Madoka Ueda and Takateru Mihara and Shinji Ito and Kunihiko Asakura and Tatsuro Mutoh",
year = "2011",
month = "4",
day = "1",
doi = "10.5692/clinicalneurol.51.243",
language = "English",
volume = "51",
pages = "243--247",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "4",

}

Hypertrophic pachymeningitis : Three adult cases and a review of the literature. / Ueda, Akihiro; Ueda, Madoka; Mihara, Takateru; Ito, Shinji; Asakura, Kunihiko; Mutoh, Tatsuro.

In: Clinical Neurology, Vol. 51, No. 4, 01.04.2011, p. 243-247.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hypertrophic pachymeningitis

T2 - Three adult cases and a review of the literature

AU - Ueda, Akihiro

AU - Ueda, Madoka

AU - Mihara, Takateru

AU - Ito, Shinji

AU - Asakura, Kunihiko

AU - Mutoh, Tatsuro

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Hypertrophic pachymeningitis (HP) is thought to have an autoimmune etiology but its precise cause and treatment remains to be elucidated. Here, we report the clinical details and therapeutic responses of 3 patients with HP and reviewed 66 previously reported cases in the literature. Among these patients, headache was the most frequent complaint. Cranial nerve involvement was also frequently observed, with the optic nerve being the most frequently impaired followed by the oculomotor, trochlear, and abducens nerves in frequency. Elevated C-reactive protein levels and erythrocyte sedimentation rates were found in approximately 97% of the patients. Steroids were the most commonly prescribed therapy, but no definite protocols for the standard dose and duration in HP have been proposed thus far. The average initial dose of prednisolone (PSL) was 42.7 mg/day, and the average maintenance dose was 12.4 mg/day in the chronic stage. Recurrence occurred in many patients when the dose of PSL was reduced to under 20 mg/day. Therefore, steroids should be tapered extremely slowly.

AB - Hypertrophic pachymeningitis (HP) is thought to have an autoimmune etiology but its precise cause and treatment remains to be elucidated. Here, we report the clinical details and therapeutic responses of 3 patients with HP and reviewed 66 previously reported cases in the literature. Among these patients, headache was the most frequent complaint. Cranial nerve involvement was also frequently observed, with the optic nerve being the most frequently impaired followed by the oculomotor, trochlear, and abducens nerves in frequency. Elevated C-reactive protein levels and erythrocyte sedimentation rates were found in approximately 97% of the patients. Steroids were the most commonly prescribed therapy, but no definite protocols for the standard dose and duration in HP have been proposed thus far. The average initial dose of prednisolone (PSL) was 42.7 mg/day, and the average maintenance dose was 12.4 mg/day in the chronic stage. Recurrence occurred in many patients when the dose of PSL was reduced to under 20 mg/day. Therefore, steroids should be tapered extremely slowly.

UR - http://www.scopus.com/inward/record.url?scp=79956306603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956306603&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.51.243

DO - 10.5692/clinicalneurol.51.243

M3 - Article

C2 - 21595292

AN - SCOPUS:79956306603

VL - 51

SP - 243

EP - 247

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 4

ER -